<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">Even though little is known on HPV genotypes circulating among HIV-infected women in SSA countries, recommendations for HPV vaccination in the population of people living with HIV (PLHIV) are still unclear [
 <xref ref-type="bibr" rid="CR7">7</xref>]. Of note, Generally 66% of infections are cleared at 12 months and this increases to 90% at 24 months [
 <xref ref-type="bibr" rid="CR8">8</xref>]. For 10% of HPV-infected individuals, there is viral persistence that remains at latency. In this frame, immunodeficiency may be the cause of viral persistence and reactivation subsequently [
 <xref ref-type="bibr" rid="CR7">7</xref>, 
 <xref ref-type="bibr" rid="CR9">9</xref>].
</p>
